Adjuvant Therapy in Renal Cell Carcinoma

Co-Host: Alexander Kutikov, MD, FACS At the conclusion of these activities, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC. 2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy. 3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC. CME Available: auau.auanet.org/node/26087 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma